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ACE2 – angiotensin converting enzyme 2  
ACEI – angiotensin converting enzyme inhibitor 
ARB – angiotensin II receptor blocker 
ARDS – acute respiratory distress syndrome 
CD4 – cluster of differentiation 4 
CRP –C reactive protein  
IL-6 – interleukin 6 
RNA – ribonucleic acid 
SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2 
TMPRSS2 – transmembrane protease, serine 2 
  
High risk patients requiring hospitalisation for severe SARS-CoV-2 infection are 
those over 60 years old, males, the obese, smokers, and those with common 
comorbidities including hypertension, cardiovascular disease, diabetes, and chronic 
lung disease.1 In one meta-analysis, the relative risk for experiencing severe versus 
non-severe COVID-19 disease was 58%, 59% and 71% higher in patients with 
hypertension, respiratory disease and cardiovascular disease respectively.1 Use of 
angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers 
(ARB)  for hypertension, heart failure and diabetes may up-regulate expression of 
ACE2, the latter being involved in the binding of SARS-CoV-2 to lung epithelium.2 
ACE2 may also be unregulated by smoking. It remains unclear whether the 
increased risk of COVID-19 infection is attributable to hypertension or age related 
comorbidity per se. Current hypertension or heart failure guidelines do not advocate 
stopping or switching ACE inhibitors or ARB’s. 
 
Upstream therapeutic strategies revolve around the use of antivirals. One study 
showed no benefit in using lopinavir plus ritonavir over standard of care for 
hospitalized adult patients with severe COVID-19 pneumonia even though the study 
was likely underpowered.3 This in turn perhaps infers that using upstream anti-viral 
therapy alone may not be successful later on in the disease process once the 
downstream cytokine avalanche has been triggered, resulting in subsequent lung 
damage. Having said that compassionate use of iv remdesivir in 53 patients with 
severe COVID-19 infection resulted in 68% having improved oxygenation status and 
18% mortality among those receiving invasive ventilation.4 There has also been 
interest in using azithromycin for COVID-19. It has been included in the ACTION 
(NCT04332107) and HyAzOUT (NCT04334382) trials on the basis of its 
immunomodulatory and putative anti-viral activity, although its effects on SARS-CoV-
2 remains speculative.5 Caution is advised in trials evaluating azithromycin in 
conjunction with hydroxychloroquine (NCT04335552), due to potential additive 
effects on QT interval prolongation. 
 
Blocking viral host cell entry with the antimalarial drugs hydroxychloroquine or 
chloroquine is another potential upstream modality. Hydroxychloroquine is safer and 
more potent in terms of in vitro SARS-CoV-2 suppression.6, 7 Hydroxychloroquine 
acts via ACE2 and increases endosomal pH to attenuate SARS-CoV-2 endocytic 
host cell entry into the lung epithelium. Hydroxychloroquine has shown some 
promising preliminary clinical results in terms of attenuating in vivo SARS-CoV-2 viral 
load5 and has been included in the WHO SOLIDARITY trial as well as the NIHR 
RECOVERY and PRINCIPLE trials. Hydroxychloroquine may also exhibit 
downstream immunosuppressive effects by reducing IL6 production from T cells and 
monocytes,8 which may explain in part its use in autoimmune conditions. Bromhexine 
is an over-the-counter cough remedy that blocks receptor mediated viral cell entry via 
the transmembrane protease, serine 2 (TMPRSS2) enzyme.9 Theoretically, there 
could be potential synergy in terms of more effectively blocking viral host cell entry 
using combined hydroxychloroquine and bromhexine (NCT04340349), but at present 
this only remains speculative. It remains to be seen whether such agents are more 
likely to be effective early on in COVID-19 disease given that they prevent viral entry. 
 
Little consideration appears to have been given to susceptible patients with 
obstructive airways disease with regards to COVID-19 infection. In particular, elderly 
COPD patients have impaired respiratory reserve and a plethora of comorbidities, 
which potentially confers both pathophysiological and pharmacological susceptibility. 
Such individuals are at high risk of adverse outcomes as a result of severe SARS-
CoV-2 infection. COPD patients taking inhaled corticosteroid (ICS) combination 
therapy have an increased pneumonia risk, especially with lipophilic drugs such as 
fluticasone furoate10 due to its prolonged lung retention and associated local 
immunosuppression in the presence of altered lung microbiome and impaired 
mucociliary clearance.11 Moreover, suppression of interferon by fluticasone 
propionate is associated with an increased bacterial load following rhinovirus 
infection.12 Corticosteroids may also attenuate production of the antibacterial 
protective peptide cathelicidin in the lung epithelium.13 Thus, secondary bacterial 
infection might contribute to the cumulative inflammatory burden in addition to viral 
pneumonia. Caution should be exercised in extrapolating from COPD to asthma, 
even though up to 20% of COPD patients have a corticosteroid responsive 
eosinophilic component. Hence, in COPD patients with blood eosinophils ≥300 
cells/µl the benefit of fluticasone furoate in reducing severe exacerbations outweighs 
its risk in inducing severe pneumonia.14 Nevertheless, one Canadian cohort study of 
asthma patients demonstrated that current ICS use was associated with a 45% 
relative increased risk of pneumonia, amounting to an excess of 1.44 cases per 
1,000 patient years.15 
 
Interestingly, ciclesonide and mometasone, but not budesonide, beclomethasone or 
fluticasone, exhibit in vitro suppression of SARS-CoV-2 replication to a similar 
degree as lopinavir.16 For ciclesonide, its target on viral replication appears to be 
non-structural protein 15 (NSP15). Budesonide and formoterol independently 
suppress systemic suppression of IL6 in relation to acute lung injury in the mouse 
model.17 Pointedly, asthmatics taking ICS are 49% less likely to have a severe 
outcome following hospitalization for influenza A/H1/N1 infection, perhaps inferring a 
generic protective ICS class effect. In the meantime, the key message for asthma 
patients is to adhere to their ICS controller therapy as this is likely to offer the best 
protection against any viral insult including SARS-CoV-2. At this juncture, no 
evidence can support switching controlled asthma patients to inhaled ciclesonide or 
mometasone. A study evaluating ciclesonide in South Korea will look at the rate of 
SARS-CoV-2 eradication in patients with mild COVID-19 infection (NCT04330586). 
Another study comparing ciclesonide with usual care from Japan will report on 
progression of severe COVID pneumonia. 
  
Corticosteroids may be considered as a rather blunt tool for dealing with the cytokine 
cascade in COVID-19 infection as they exhibit a broad-spectrum suppressive effect 
on cytokines. Systemic corticosteroids are part of the routine management of acute 
viral exacerbations of asthma and COPD and are effective at treating the eosinophilic 
component of type 2 inflammation.18 Corticosteroids may also suppress host immune 
responses and increase viral replication which is reversed by adjuvant interferon.19 A 
study with inhaled interferon-beta-1a (SNG001) will evaluate whether up-regulating 
lung antiviral defenses is effective in COVID-19 illness, while other trials will evaluate 
subcutaneous interferon-beta-1a with lopinavir/ritonavir (NCT04315948). One might 
postulate that nebulized interferon-beta-1a may not achieve adequate alveolar drug 
concentrations in severe COVID-19 infection since by the same token nebulized 
antibiotics are not effective in bacterial pneumonia. 
 
SARS-CoV-2 infection may induce a profound downstream cytokine cascade 
involving IL1, IL6, IL12 and TNF-α (Figure).20 This release of cytokines is followed by 
rapid development of lung tissue damage resulting in ARDS, sepsis and organ 
failure, which may require assisted ventilatory support and extracorporeal membrane 
oxygenation. One study in severe COVID-19 infection found that the risk of 
respiratory failure in patients with circulating IL6 levels >80pg/ml was 22 fold higher 
with a median time to mechanical ventilation of 1.5 days.21 
 
A more selective approach is therefore required to address the downstream cytokine 
storm. Recent attention has centered around the possibility of therapeutic 
intervention with anti-IL6 drugs such as tocilizumab and sarilumab which are 
indicated for rheumatoid disease. There is emerging evidence that they may also be 
useful when repurposed for severe SARS-CoV-2 infection in terms of dampening the 
downstream cytokine response and the associated hyperinflammatory syndrome, the 
latter primarily characterized by secondary hemophagocytic lymphohistiocytosis. 
 
A compassionate use study from China in 21 patients infected with SARS-CoV-2 
using the anti-IL6 agent tocilizumab showed a rapid reduction in fever, C reactive 
protein (CRP) and oxygen requirement along with improved radiological 
appearances and normalization of lymphocyte counts within 5 days of administration 
of a single 400mg dose.22 Moreover 90% of patients were discharged within a mean 
hospitalization period of 13.5 days after tocilizumab. All patients already had routine 
treatment for 1 week including lopinavir and methylprednisolone prior to receiving 
tocilizumab. A significant limitation may therefore be survival bias in that sicker 
patients would be expected to have rapidly deteriorated within the first week of 
hospitalised illness. Evidently these data need urgent replication ideally in 
randomised controlled trials. A study is now under way recruiting hospitalized 
patients with SARS-CoV-2 (NCT04315298) using the anti-IL6 agent sarilumab, while 
three other studies are evaluating tocilizumab alone: COVACTA (NCT04320615) and 
TOCOVID (NCT04322773), or in combination with favipiravir (NCT04310228). We 
would advocate that patients with severe COVID-19 infection should be screened for 
biomarkers of hyperinflammation including rising CRP, ferritin, D-dimer, plasma 
viscosity, and cytopenia including falling platelet count, as these may highlight at-risk 
patients where IL6 suppression could be beneficial. 
 
There are cogent reasons to suggest that a combined treatment modality might be 
required to obviate upstream SARS-CoV-2 lung tissue binding with 
hydroxychloroquine or bromhexine and downstream IL6 blockade by sarilumab or 
tocilizumab (Figure). With this in mind we believe studies are urgently warranted to 
investigate such combination therapy in older susceptible individuals with 
comorbidities who are at high risk for developing severe COVID-19 pneumonia. 
Ultimately the indications for such combined therapies will be determined by factors 
such as stage of disease, safety, cost and route of administration. 
 
Key learning points: 
 
• Severe SARS-CoV-2 infection with poor outcomes occurs in older susceptible 
patients who may be obese, smokers, and with multiple comorbidities. 
 
• Patients with eosinophilic asthma and COPD should continue to use ICS 
containing therapy to maintain optimal control and protect against viral insults 
including SARS-CoV-2 infection.  
 
• Antiviral therapy such as lopinavir-ritonavir may not be successful unless 
used earlier in the course of COVID-19 infection. 
 
• More severe COVID-19 infection may produce a cytokine storm associated 
with hyperinflammatory syndrome and hemophagocytic lymphohistiocytosis, 
with IL6 levels being highly predictive of respiratory failure. 
 
• Screening for biomarkers of hyperinflammation such as cytopenia, CRP, D-
dimer, plasma viscosity, and ferritin may identify at-risk patients where 
cytokine suppression may be beneficial. 
 
• Clinical trials are urgently warranted to evaluate a combined therapeutic 
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Depicts the cytokine cascade resulting from acute severe SARS-CoV-2 infection, 
with downstream IL-6 activation considered to be a hallmark feature in terms of 
progression of COVID-19 pneumonia to hyperinflammation and ARDS. Also shown 
are the putative mechanisms of action for bromhexine and hydroxychloroquine in 
attenuating upstream SARS-CoV-2 tissue binding, the effect of antivirals on 
replication, azithromycin as an immunomudulator, non-specific cytokine suppression 
by corticosteroids, together with downstream effect of IL-6 blockade with tocilizumab 
or sarilumab. 

